The synergistic activity of NK cell activation and PD-1/PD-L1 blockade has recently been demonstrated for the combination of the NKG2A targeting antibody Monalizumab with the PD-L1 targeting antibody Durvalumab in patients with advanced NSCLC [42]. Here, KLRC1 is linked to non-small cell lung carcinoma.